Tuesday, August 9, 2016

AstraZeneca drug selumetinib fails in lung cancer study

LONDON, Aug 9 (Reuters) - AstraZeneca's cancer drug

pipeline suffered a setback on Tuesday when the experimental

drug selumetinib failed to meet its goal in a late-stage trial

for lung cancer.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)